Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced ... Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance ...

Intravesical instillation with live, attenuated Mycobacterium Bacillus Calmette-Guérin (BCG ... risk and high-risk bladder cancer. BCG immunotherapy showed a significant advantage over mitomycin ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG ... and Drug Administration approved ImmunityBio's immunotherapy Anktiva to treat patients with NMIBC ...

Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...

IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive ...

Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis live, attenuated culture preparation; 50mg per vial; pwd for intravesical administration after reconstitution and dilution ...

The standard treatment for non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guérin (BCG). However, despite it being effective, many patients experience recurrences, and others become ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company developing ... of bladder cancer in combination with BCG (Bacillus Calmette-Guérin). The company has implemented a ...